Cagrilintide vs Semaglutide

Long-acting amylin analogue; acts on amylin/calcitonin receptors to prolong satiety; synergistic with semaglutide in CagriSema combination

Cagrilintide is a long-acting synthetic amylin analogue under clinical development for obesity, designed to mimic the satiety-promoting and gastric-emptying-reducing actions of the endogenous beta-cell hormone amylin. By activating amylin receptors in the hindbrain, cagrilintide reduces caloric intake and body weight, and the drug is also being co-developed with the GLP-1 receptor agonist semaglutide (CagriSema) to target multiple appetite-regulating pathways simultaneously. Phase 2 randomized controlled trials published in The Lancet have demonstrated meaningful weight reduction in people with overweight and obesity, establishing proof of concept for both monotherapy and combination approaches. Cagrilintide is an investigational compound that has not yet received FDA approval; it remains in late-stage clinical development as of 2025.

Semaglutide is a GLP-1 receptor agonist that mimics the incretin hormone GLP-1, stimulating glucose-dependent insulin secretion, suppressing glucagon release, and slowing gastric emptying. Central GLP-1 receptor activation in the hypothalamus and brainstem reduces appetite and caloric intake. Its extended half-life of approximately seven days is achieved via structural modifications including a C18 fatty diacid chain enabling reversible albumin binding.

Semaglutide is a GLP-1 receptor agonist approved by the FDA for type 2 diabetes (Ozempic) and chronic weight management (Wegovy). It is among the most prescribed and searched compounds in the weight loss space. Compounding pharmacies have produced semaglutide formulations under 503A and 503B frameworks, with significant provider interest across the telehealth and functional medicine space. Mechanism of action: Semaglutide activates glucagon-like peptide-1 (GLP-1) receptors in the hypothalamus, brainstem, and pancreas. This triggers a coordinated metabolic response: appetite signals are reduced, gastric emptying is slowed (increasing satiety duration), insulin secretion is potentiated in a glucose-dependent manner, and glucagon secretion is suppressed. The result is reduced caloric intake and improved postprandial glucose regulation. Semaglutide's extended half-life (~7 days) enables once-weekly subcutaneous injection, distinguishing it from earlier GLP-1 agonists that required daily dosing. Clinical evidence: The STEP trial program established semaglutide's weight reduction profile. STEP 1 (2021) found a mean weight reduction of 14.9% over 68 weeks with 2.4mg/week semaglutide (Wegovy dose) vs 2.4% with placebo. STEP 4 demonstrated that discontinuation led to weight regain, indicating ongoing use is required to maintain outcomes. The SUSTAIN trial series confirmed cardiovascular risk reduction in T2D patients. Semaglutide is one of the most extensively studied GLP-1 agonists in large-scale randomised controlled trials. Semaglutide with B12: Some compounding formulations combine semaglutide with vitamin B12 (methylcobalamin) in the same injectable preparation. The rationale is two-fold: nausea and gastrointestinal discomfort are the most commonly reported side effects of GLP-1 agonists (occurring in 15–40% of users in trials), and injectable methylcobalamin bypasses the reduced gastric absorption that can accompany slowed gastric motility. B12 also supports energy metabolism during periods of caloric restriction. Clinical evidence that B12 addition changes weight loss outcomes is limited; the combination is primarily a compounding convention rather than a protocol validated in independent clinical trials. Providers offering compounded semaglutide with B12 formulations are indexed in the PeptideBase directory. Semaglutide vs tirzepatide: Semaglutide is a single GLP-1 receptor agonist; tirzepatide is a dual agonist targeting both GLP-1 and GIP receptors. The SURMOUNT-5 head-to-head trial found tirzepatide produced greater weight reductions than semaglutide at comparable doses. Both are FDA-approved and available through licensed prescribers; protocol selection depends on clinical context and provider judgment.